IV drips and injections: separating wellness hype from evidence

What's this video probably claiming?

@holisticinjectors is pitching a mobile or clinic-based IV therapy and injection service, likely covering glutathione, B12, NAD+, and possibly peptides like BPC-157 or CJC-1295 given the hashtag category. The core pitch appears to be three things: licensed providers deliver these treatments, ingredients are "pure" and therefore fully absorbable, and protocols are customized per client. The implicit message threading all of this together is that IV delivery means superior absorption compared to oral supplements, and that their sourcing standards make a clinical difference. These are claims that sound reasonable on the surface but carry real scientific baggage when you pull on them.

What does the science actually show?

On B12: oral high-dose supplementation (1000-2000 mcg daily) has been shown to correct deficiency comparably to intramuscular injection in multiple randomized trials, including Kuzminski et al. (1998, Blood) and a 2018 Cochrane review by Vidal-Alaball et al. The absorption argument for IV B12 falls apart quickly unless the patient has documented malabsorption, pernicious anemia, or a confirmed deficiency. For glutathione, IV infusions do transiently raise plasma glutathione levels, as shown by Kern et al. (2011, Parkinsonism and Related Disorders), but whether that translates to meaningful tissue-level antioxidant activity in healthy adults is genuinely unclear. NAD+ infusions do raise blood NAD+ levels per Martens et al. (2023, Nature Aging), but clinical benefit in non-deficient populations remains speculative. Peptides in this category have even thinner human trial data.

Where does the social media noise diverge from clinical reality?

The "pure ingredients equal full absorption" framing is marketing language dressed up as biochemistry. IV delivery does bypass first-pass metabolism and gut absorption, that part is true. But bioavailability is not the same as clinical efficacy. Your body excretes or redistributes nutrients it does not need, regardless of how they were delivered. The FDA does not regulate IV compounded solutions the same way it regulates approved drugs, and the American Society of Health-System Pharmacists has flagged quality control variability in compounded IV preparations repeatedly. The "customization" pitch is also worth scrutinizing: without baseline bloodwork confirming a deficiency, customization is mostly aesthetic. A 2022 analysis in JAMA Internal Medicine found that the majority of IV wellness infusion recipients had no documented clinical indication for the nutrients they received.

What should you actually know?

If you are genuinely deficient in B12, magnesium, or another micronutrient, IV or IM delivery may be appropriate and is standard care. If you are not deficient, you are mostly paying to make expensive urine. Glutathione injections are popular as a skin-lightening agent in parts of Asia and elsewhere, and the FDA has issued warnings about safety risks including thyroid dysfunction and kidney damage from unlicensed products. NAD+ infusions carry a real side effect profile including nausea, flushing, and chest pressure, and are not trivial to administer safely. Peptides like BPC-157 and CJC-1295 are not FDA-approved for human use and exist in a regulatory gray zone. Anyone offering these should be clearly disclosing that status to patients. Legitimate providers do exactly that.